Proposed herein is the development of new chemistry for the de novo synthesisof carbohydrates and the use of this new methodology for the synthesis of new bioactivemolecules. These new bioactive structures may have activities against a range ofdiseases. This proposal is focus on anticancer and antibacterial compounds. Theapproach toward cancer is to use this new methodology to preform novel SAR studieson the carbohydrate portion of known natural products with anticancer activity. Thisapproach will be conducted on the carbohydrate portions of digitoxin, SL0101 andLandomycin A. With regard to antibacterial agents this proposal is focused onaddressing the problem of bacterial resistance. The major objectives of this proposal are to develop a concise methodologytoward unnatural sugars, to develop a method for the assembly of unnatural sugars intounnatural oligosaccharides and to incorporate these unnatural sugars into carbohydratebased antibiotics, etc. Having unnatural sugar analogues of these antibiotics/antitumoragents would greatly aid in revealing which functional groups are important to thesemolecular interactions and in turn help prepared new more potent drugs.
This proposal intends to apply our palladium-catalyzed glycosylation for the de novo syntheses of several carbohydrate containing natural products and related compounds with important biological activities. These activities range from antibacterial to potential new cancer therapies. The long range expected outcome from this research effort is to develop and demonstrate a new methodology that will enable a medicinal chemist to mimic nature's use of rare and unnatural sugars in the Structure Activity Relationship (SAR) study of bioactive molecules. We anticipate that our Sugar Replacement Strategy, which installs simple sugars (i.e., under functionalized) into complex structural motifs, will drastically enable carbohydrate based drug discovery. This belief is based on the premise that there are many carbohydrate structures, which remain undiscovered because of synthetic limitations. Thus, allowing the discovery of new drugs (e.g., new antibiotics with activity towards multi-drug-resistant (MDR) bacteria, new anticancer agents, etc.). E. Human Subjects Not Applicable F. Vertebrate Animals Not Applicable
Showing the most recent 10 out of 19 publications
